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Abstract
Background: The diagnosis and antimicrobial treatment of pneumonia in African children in the absence of
diagnostic means such as x-ray facilities or microbiological laboratories relies primarily on clinical symptoms
presented by the patients. In order to assess the spectrum of bacterial pathogens, blood cultures were performed
in children fulfilling the clinical criteria of pneumonia.
Methods: In total, 1032 blood cultures were taken from children between 2 months and 5 years of age who were
admitted to a rural hospital in Ghana between September 2007 and July 2009. Pneumonia was diagnosed clinically
and according to WHO criteria classified as “non-severe pneumonia” and “severe pneumonia” ("severe pneumonia”
includes the WHO categories “severe pneumonia” and “very severe pneumonia”).
Results: The proportion of bacteriaemia with non-typhoid salmonella (NTS) was similar in children with pneumonia
(16/173, 9.2%) compared to children hospitalized for other reasons (112/859, 13%). NTS were the predominant
organisms isolated from children with clinical pneumonia and significantly more frequent than Streptococcus
pneumoniae (8/173, 4.6%). Nine percent (9/101) of children presenting with severe pneumonia and 10% (7/72) of
children with non-severe pneumonia were infected with NTS. Nineteen out of 123 NTS isolates (15%) were
susceptible to aminopenicillins (amoxycillin/ampicillin), 23/127 (18%) to chlorampenicol, and 23/98 (23%) to co-
trimoxazole. All NTS isolates were sensitive to ceftriaxone and ciprofloxacin.
Conclusion: In Sub-saharan Africa, sepsis with NTS should be considered in children with symptoms of pneumonia
and aminopenicillins might often not be the adequate drugs for treatment.
Background
Pneumonia is one of the most common diagnoses in
African children presenting at hospitals and peripheral
health centres and is the most important cause of mor-
tality in children under five years of age [1,2]. Due to
the lack of bacteriological laboratory facilities, antibiotic
treatment of pneumonia is guided by presumptions
based on clinical symptoms. According to the WHO-
IMCI (World Health Organisation Integrated Manage-
ment of Childhood Illness) amoxicillin is the first line
drug for empirical treatment of pneumonia as it covers
the commonly suspected organisms (e.g. Streptococcus
pneumoniae and Haemophilus influenzae) [3]. However,
this treatment scheme does not capture enteric bacteria
and there is some evidence that Gram-negative bacteria
such as Salmonella spp. occur more frequently among
African children with septic pneumonia than expected.
Among 166 Kenyan children with blood cultures posi-
tive for non-typhoidal salmonella (NTS), 46% fulfilled
the clinical criteria of pneumonia according to WHO-
IMCI. On the other hand, bacteraemia due to NTS was
not associated with diarrhoea [4]. In other reports from
East, West and Central Africa, the impact of NTS in
systemic infections was recognized as well [5-16]. More-
over, NTS were among the most frequent organisms
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isolated from children with clinical pneumonia in some
studies that were carried out before the vaccination
against H. influenzae (Hib-vaccination) was introduced
[14,17-19]. In the context of an improving coverage of
Hib and pneumococcal immunisations, the impact of
NTS as a cause of pneumonia will, most likely, increase
considerably among African children [20].
In the present study, blood cultures were performed in
children admitted to a rural hospital with pneumonia
symptoms according to the WHO-IMCI definition in
order to quantify the impact of systemic infections with
NTS and to assess antibiotic drug resistance patterns.
Methods
Study site
The study hospital is located in the village Agogo in the
Asante Akim North District of the Ashanti Region in
Ghana, West Africa, and is the principal hospital of the
district. Its catchment population encompasses approxi-
mately 80,000 people with roughly 25,000 citizens of
Agogo itself. The HIV/AIDS prevalence in the area is
around 1.9% according to the National AIDS Control
Programme in 2009. Vaccination programmes against
H. influenzae have been established in 2001.
Study population
Between September 2007 and July 2009, 948 children
between 2 months and 5 years of age who were hospita-
lized and from whom a blood culture was taken were
included into the study. In total, 1032 blood cultures
were taken during 1169 hospitalizations. The study
complied with the “Ethical Principles for Medical
Research Involving Human Subjects” as laid out in the
Declaration of Helsinki and was approved by the Com-
mittee on Human Research Publications and Ethics
(CHRPE) of the School of Medical Sciences, Kumasi,
Ghana. Informed consent was sought from the parents
or the guardians of the child after detailed explanation
of the study and the study procedures.
Clinical pneumonia, case classification
Pneumonia was classified following established WHO
guidelines [21]. Children with cough or difficult breath-
ing were classified as “pneumonia cases” if they had an
increased respiratory rate of ≥ 50 per minute in children
of 2 months up to 11 months of age and ≥ 40 per min-
ute in children of 12 months up to 5 years of age. Chil-
dren with symptoms of lower chest wall indrawing,
nasal flaring, grunting (in young children) and/or sub-
costal retraction or additional signs of central cyanosis,
severe respiratory distress, vomiting everything or inabil-
ity to breastfeed/drink, or other danger signs were clas-
sified as “severe pneumonia” (including the WHO
definitions for “very severe pneumonia” and “severe
pneumonia”).
Blood cultures
1-3 ml of venous blood was taken from hospitalized
children and directly injected into a Becton Dickinson
(BD) BACTEC™ PEDS PLUS™/F bottle containing 20 ml
of enriched broth with resin. The bottles were incubated
at 35°C in a BD BACTEC™ 9050 automated Blood Cul-
ture system (BD Diagnostics, Sparks, Massachussets,
USA) [22] for 5 days or until rated positive. Broth from
positive bottles was directly examined by Gram stain
and 20 μl were cultured further on sheep blood-agar,
chocolate-agar and MacConkey agar (prepared in-house
from Oxoid dehydrated media). Agar plates were incu-
bated at 37°C for 18-24 h. Microscopical diagnosis after
Gram staining was immediately reported to the clinical
staff. Identification of S. pneumoniae was based on mor-
phology of colonies and the optochin test. Oxacillin
discs were used to determine sensitivity to penicillin.
Diphteroids and propionibacteriae were classified as
contaminants. If the patient was not known to be HIV
positive, coagulase negative staphylococci, bacillus spe-
cies and non-fermenters were usually also classified as
contaminants. On the same day, antibiotic susceptibility
testing was performed using the disc diffusion method
with the susceptibility breakpoints suggested by the
Clinical and Laboratory Standards Institute (CLSI). The
following antibiotics were tested: amoxycillin/ampicillin,
amoxyclav (amoxicillin & clavulanic acid), cefuroxime,
ceftriaxone, co-trimoxazole, ciprofloxacin, gentamicin,
tetracycline and chloramphenicol. The microbiological
laboratory that was involved in the study is enrolled in a
quarterly external quality assurance program in bacter-
iology from the National Institute for Communicable
Diseases (NICD) of South Africa. If blood cultures that
were taken from the same child presenting twice within
2 weeks yielded identical results, only the first result
was included into further analyses.
Data collection and statistical analysis
At admission of children, clinical data were recorded on
standardized forms. Data collection was entirely
embedded into the clinical routine. The admission chart
contained a 4-paged admission sheet to be filled in by
the admitting doctor. Double data entry was done by
data entry clerks using a 4th Dimension Database (©4D
San Jose, California, United States). Data analysis was
carried out using the STATA 10 software (College Sta-
tion, Texas, United States).
For each pathogen, the number of isolates and their
proportion among all blood cultures performed was cal-
culated separately for children fulfilling the case
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definition for pneumonia, severe pneumonia and for
non-cases.
Results
Of the 1032 blood cultures included, 734 (71%) did not
yield bacterial growth and 90 (9%) were positive with
non-pathogenic microorganisms (contaminants).
Pathogens were isolated from the remaining 208 (20%)
blood cultures. Antiobiotic pre-medication was
reported from 7% of children and was independent of
the positivity of blood cultures. The frequency of chil-
dren without pneumonia (12.2%), pneumonia cases
(8.9%) and severe pneumonia cases (9.8%), was similar
in children with available and with missing blood cul-
tures (p = 0.5, c2 = 1.2).
In total, 173 children fulfilled the case definition of
pneumonia of any severity. Blood cultures were positive
in 18.1% (13/72) of children with non-severe pneumonia
and in 26.7% (27/101) of children with severe pneumo-
nia. The frequency of bacteraemia was similar high in
the 859 children without pneumonia (168/859, 19.6%).
Ten children with severe pneumonia died: 2 children
with a systemic NTS infection (1 with aminopenicillin
resistant strains), 3 with S. pneumoniae bacteraemia, 1
with S. Typhi, and 4 with negative blood cultures. Fatal-
ities were not observed among the patients with non-
severe pneumonia.
Among all children with and without bacteraemia,
24% and 34% were positive for malaria parasites, respec-
tively. Children with NTS bacteraemia had more often a
co-infection with malaria parasites (24%) compared to
those with S. pneumoniae bacteraemia (18%). Malaria
co-infection was found in 35% of non-cases, 28% of
pneumonia cases and 22% of severe pneumonia cases.
In patients without pneumonia, NTS represented
66.7% (112/168), S. aureus 10.1% (17/168), S. pneumo-
niae 7.1% (12/168) and S. Typhi 6.5% (11/168) of the
pathogen isolates. In non-severe pneumonia cases NTS
represented 53.8% (7/13), S. aureus 7.7% (1/13), S. pneu-
moniae 15.4% (2/13) and S. Typhi 7.7% (1/13) of the
pathogen isolates. In severe pneumonia cases NTS
represented 33.3% (9/27), S. aureus 14.8% (4/27),
S. pneumoniae 22.2% (6/27) and S. Typhi 11.1% (3/27)
of the pathogen isolates. When looking at all pneumonia
cases of any severity, 16 of 40 (40%) of all pathogen iso-
lates were NTS (Table 1).
Sensitivity to antibiotics
All NTS and S. pneumoniae isolates from children aged
2 months to 5 years were included for sensitivity testing
against 9 antibiotics irrespective of their clinical diagno-
sis (Table 2). 15% of all NTS isolates were sensitive
to aminopenicillins (amoxycillin/ampicillin), 18% to
chloramphenicol, 23% to co-trimoxazole, and 71% to
gentamicin. All isolates of NTS were susceptible to cef-
triaxone and ciprofloxacin. The frequency of multidrug
resistance (MDR, resistance against amoxycillin, chlor-
amphenicol, and co-trimoxazole) was 75.5% (74/98).
Discussion
In the present study, non-typhoid salmonella (NTS)
were found in 10% of the blood cultures and were the
predominant cause of bacteraemia in hospitalized chil-
dren. This prevalence is, most likely, underestimated
Table 1 Blood culture results in children between 2 months and 5 years of age
All pneumonia
n = 173
Non-severe pneumonia*
n = 72
Severe pneumonia
n = 101
No pneumonia
n = 859
Total
n = 1032
n % % n % n % n %
NTS 16 9.3 7 9.7 9 8.9 112 13.0 128 12.4
S. Typhi 4 2.3 1 1.4 3 3.0 11 1.3 15 1.5
Shigella spp. 0 - 0 - 0 - 3 0.4 3 0.3
Enterococcus spp. 0 - 0 - 0 - 1 0.1 1 0.1
S. pneumoniae 8 4.6 2 2.8 6 5.9 12 1.4 20 1.9
H. influenzae 0 - 0 - 0 - 1 0.1 1 0.1
Streptococcus spp. 1 0.6 1 1.4 0 - 3 0.4 4 0.4
S. aureus 5 2.9 1 1.4 4 4.0 17 2.0 22 2.1
Klebsiella spp. 2 1.2 1 1.4 1 1.0 2 0.2 4 0.4
Pseudomonas spp. 1 0.6 0 - 1 1.0 0 - 1 0.1
Acinetobacter spp. 1 0.6 0 - 1 1.0 2 0.2 3 0.3
M. morganii 1 0.6 0 - 1 1.0 0 - 1 0.1
E. coli 1 0.6 0 - 1 1.0 4 0.5 4 0.5
Contaminant 11 6.4 5 6.9 6 5.9 79 9.2 90 8.7
Negative 122 70.5 54 75.0 68 67.3 612 71.3 734 71.1
* Pneumonia cases according to WHO-IMCI definition. Agogo Presbyterian Hospital 09/2007-07/2009
# Severe pneumonia included the WHO definitions for “very severe pneumonia” and “severe pneumonia”
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due to the small blood volumes that were available in
the paediatric patients and the frequent self-medication
with antibiotics prior to blood sampling. It has been
reported that the sensitivity of blood cultures fell by
almost one third if a blood volume of 1 ml was inocu-
lated to blood culture bottles compared to a volume of
3 ml as recommended [23].
The frequency of NTS was similar among children
with pneumonia and those without pneumonia and it
cannot be determined whether bacteraemia due to NTS
is the exclusive cause of pneumonia or predisposes to
secondary infections with other microorganisms. How-
ever, from a practical point of view this may be irrele-
vant: if NTS occur frequently among children with
severe respiratory symptoms, empirical treatment of
pneumonia must include coverage of NTS.
In Africa, aminopenicillins or co-trimoxazole are cur-
rently recommended for empirical treatment of commu-
nity-acquired pneumonia in children, assuming that the
most frequent causal infectious organisms are S. pneu-
moniae and H. influenzae. The IMCI-WHO guidelines
recommend treating non-severe pneumonia with cotri-
moxazole or amoxicillin given orally, severe pneumonia
with oral amoxicillin or injectable penicillin and very
severe pneumonia with injectable ampicillin plus inject-
able gentamicin [3].
Empirical treatment of childhood pneumonia with the
aforementioned first line drugs may readily fail due to
the high frequency of drug resistance of NTS [20]. In
the present study, only 15.5%, 23.5% and 70.9% of NTS
isolates were sensitive to aminopenicillins, co-trimoxa-
zole and gentamicin, respectively. Multi-drug resistance
against the three standard drugs amoxicillin, chloram-
phenicol and co-trimoxazole was 75.5%. High levels of
MDR have also been reported from the Democratic
Republic of Congo [24], Malawi [8,25], The Gambia
[26,27] and Kenya [28]. A study from Tanzania has
demonstrated strong association of antimicrobial resis-
tance with fatal courses of children with bloodstream
infections [29]. Fifteen years ago, no resistance to chlor-
amphenicol and 57% resistance to ampicillin was
reported in NTS collected from children in Accra,
Ghana [16]. A more recent study from Accra found
MDR in 87% of Salmonella serogroup B isolates [30]. In
Northern Ghana, among 6 isolates of Salmonella spp.
from children with diarrhoea, only one was resistant to
ampicillin and chloramphenicol [31]. This demonstrates
that marked local and temporal differences of antibiotic
resistance patterns of NTS exist [32].
Ceftriaxone or ciprofloxacin may be appropriate alter-
natives to treat bacterial infections causing pneumonia
in areas with prevalences of NTS. Notably, 50% of the
pneumococcal isolates were resistant to ciprofloxacin in
the present study compared to only 4% of all pneumo-
coccal and NTS isolates in 1997 [33]. However, the use
of ceftriaxone in low-resource countries has consider-
able disadvantages which have to be considered: (i) the
drug has to be adminstered intravenously or intramus-
cularly; (ii) well trained staff is necessary; (iii) uncritical
use may promote the development of resistance; (iv) cef-
triaxone is approximately 3 to 10 times more expensive
than amoxicillin.
Conclusion
Aminopenicillins may often not be adequate for the
treatment of children presenting with pneumonia symp-
toms in Sub-saharan Africa and NTS in children with
pneumonia should strongly be considered as possible
infectious agent. The development of alternative drugs
and, best, vaccines against NTS as well as appropriate
surveillance of this neglected infectious disease is
necessary.
Acknowledgements
We thank the chirdren and their parents for their participation in this study.
We are also grateful for the continuous endeavours of fieldworkers and
interviewers of the Kumasi Centre for Collaborative Research in Tropical
Medicine (KCCR), and to the staff of the Public Health Unit of the Agogo
Presbyterian Hospital for their collaboration. We gratefully acknowledge the
financial support received from a Swiss Foundation. The findings and
conclusions in this paper are those of the authors and do not necessarily
represent the views of any of their affiliated Research Institutions.
Author details
1Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany. 2Kumasi
Centre for Collaborative Research in Tropical Medicine, Kumasi, Ghana.
3International Vaccine Institute, Seoul, South Korea. 4University Hospital of
Wales, Cardiff, UK. 5School of Medical Sciences, Kwame Nkrumah University
of Science and Technology, Kumasi, Ghana.
Authors’ contributions
Authors contribution: JM, CGM, JAE, and YAS planned and initiated the
study. NS organised the day-to-day work as study coordinator. FH planned
Table 2 Proportion susceptible to antibiotics among NTS
and S. pneumoniae isolates
NTS* (N = 128) S. pneumoniae*
(N = 20)
%
susceptible
n
tested
%
susceptible
n
tested
Amoxycillin/
Ampicillin
15.5% 123 80.0% 20
Amoxyclav 25.7% 113 88.9% 18
Cefuroxime 46.5% 127 100% 6
Ceftriaxone 100% 108 100% 14
Co-trimoxazole 23.5% 98 0% 17
Ciprofloxacin 100% 127 52.6% 19
Gentamicin 70.9% 127 22.2% 18
Tetracyclin 89.0% 91 25.0% 16
Chloramphenicol 18.1% 127 88.9% 18
*Blood cultures from children aged 2 months to 5 years of age. Agogo
Presbyterian Hospital 09/2007-07/2009
Schwarz et al. BMC Infectious Diseases 2010, 10:319
http://www.biomedcentral.com/1471-2334/10/319
Page 4 of 5
and established the microbiological laboratory facilities at the Agogo
Presbyterian Hospital. SEKA, AA and BN carried out the microbiological
cultures and antimicrobial resistance testing. DD substantially contributed to
microbiological work-up and the preparation of the manuscript. RMH, JF and
FM contributed to the analysis and the writing of the manuscript. WL
created Case Record Forms and was responsible for data management and
data preparation for analyses. NGS designed the analysis protocol and
analysed the data. JM, NGS, and CGM wrote the manuscript. All authors
have read and approved to the final version of this manuscript. Parts of this
research have been financially supported by a Swiss Foundation.
Competing interests
The authors declare that they have no competing interests.
Received: 10 May 2010 Accepted: 4 November 2010
Published: 4 November 2010
References
1. World Health Organisation: The global burden of disease: 2004 update
(2008). WHO, Geneva; 2008 [http://www.who.int/healthinfo/
global_burden_disease/2004_report_update/en/index.html], accessed
26.10.2009.
2. You D, Wardlaw T, Salama P, Jones G: Levels and trends in under-5
mortality, 1990-2008. Lancet 2010, 375(9709):100-103.
3. World Health Organisation: Technical update of the guidelines on the
Integrated Managment of Childhood Illness (IMCI): evidence and
recommendations for further adaptations. WHO, Geneva; 2005.
4. Brent AJ, Oundo JO, Mwangi I, Ochola L, Lowe B, Berkley JA: Salmonella
bacteremia in Kenyan children. Pediatr Infect Dis J 2006, 25(3):230-236.
5. Mankhambo LA, Chiwaya KW, Phiri A, Graham SM: Lobar pneumonia
caused by nontyphoidal Salmonella in a Malawian child. Pediatr Infect Dis
J 2006, 25(12):1190-1192.
6. Cheesbrough JS, Taxman BC, Green SD, Mewa FI, Numbi A: Clinical
definition for invasive Salmonella infection in African children. The
Pediatric infectious disease journal 1997, 16(3):277-283.
7. Evans JA, Adusei A, Timmann C, May J, Mack D, Agbenyega T,
Horstmann RD, Frimpong E: High mortality of infant bacteraemia
clinically indistinguishable from severe malaria. QJM 2004, 97(9):591-597.
8. Graham SM, Walsh AL, Molyneux EM, Phiri AJ, Molyneux ME: Clinical
presentation of non-typhoidal Salmonella bacteraemia in Malawian
children. Transactions of the Royal Society of Tropical Medicine and Hygiene
2000, 94(3):310-314.
9. Green SD, Cheesbrough JS: Salmonella bacteraemia among young
children at a rural hospital in western Zaire. Ann Trop Paediatr 1993,
13(1):45-53.
10. Lepage P, Bogaerts J, Van Goethem C, Ntahorutaba M, Nsengumuremyi F,
Hitimana DG, Vandepitte J, Butzler JP, Levy J: Community-acquired
bacteraemia in African children. Lancet 1987, 1(8548):1458-1461.
11. Mandomando I, Macete E, Sigauque B, Morais L, Quinto L, Sacarlal J,
Espasa M, Valles X, Bassat Q, Aide P, et al: Invasive non-typhoidal
Salmonella in Mozambican children. Trop Med Int Health 2009,
14(12):1467-1474.
12. Morpeth SC, Ramadhani HO, Crump JA: Invasive non-Typhi Salmonella
disease in Africa. Clin Infect Dis 2009, 49(4):606-611.
13. Nesbitt A, Mirza NB: Salmonella septicaemias in Kenyan children. J Trop
Pediatr 1989, 35(1):35-39.
14. O’Dempsey TJ, McArdle TF, Lloyd-Evans N, Baldeh I, Laurence BE, Secka O,
Greenwood BM: Importance of enteric bacteria as a cause of pneumonia,
meningitis and septicemia among children in a rural community in The
Gambia, West Africa. The Pediatric infectious disease journal 1994,
13(2):122-128.
15. Walsh AL, Phiri AJ, Graham SM, Molyneux EM, Molyneux ME: Bacteremia in
febrile Malawian children: clinical and microbiologic features. The
Pediatric infectious disease journal 2000, 19(4):312-318.
16. Wilkens J, Newman MJ, Commey JO, Seifert H: Salmonella bloodstream
infection in Ghanaian children. Clin Microbiol Infect 1997, 3(6):616-620.
17. Berkley JA, Maitland K, Mwangi I, Ngetsa C, Mwarumba S, Lowe BS,
Newton CR, Marsh K, Scott JA, English M: Use of clinical syndromes to
target antibiotic prescribing in seriously ill children in malaria endemic
area: observational study. BMJ (Clinical research ed 2005, 330(7498):995.
18. Graham SM, Mtitimila EI, Kamanga HS, Walsh AL, Hart CA, Molyneux ME:
Clinical presentation and outcome of Pneumocystis carinii pneumonia in
Malawian children. Lancet 2000, 355(9201):369-373.
19. Sigauque B, Roca A, Mandomando I, Morais L, Quinto L, Sacarlal J,
Macete E, Nhamposa T, Machevo S, Aide P, et al: Community-acquired
bacteremia among children admitted to a rural hospital in Mozambique.
The Pediatric infectious disease journal 2009, 28(2):108-113.
20. Graham SM, English M: Non-typhoidal salmonellae: a management
challenge for children with community-acquired invasive disease in
tropical African countries. Lancet 2009, 373(9659):267-269.
21. World Health Organisation: Pocket book of hospital care for children:
guidelines for the management of common illnesses with limited
ressources. WHO, Geneva; 2005.
22. Eisenach K, Dyke J, Boehme M, Johnson B, Cook MB: Pediatric blood
culture evaluation of the BACTEC PEDS Plus and the DuPont Isolator 1.5
systems. Diagn Microbiol Infect Dis 1992, 15(3):225-231.
23. Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, Mwarumba S, Ngetsa C,
Slack MP, Njenga S, Hart CA, et al: Bacteremia among children admitted
to a rural hospital in Kenya. N Engl J Med 2005, 352(1):39-47.
24. Bahwere P, Levy J, Hennart P, Donnen P, Lomoyo W, Dramaix-Wilmet M,
Butzler JP, De Mol P: Community-acquired bacteremia among
hospitalized children in rural central Africa. Int J Infect Dis 2001,
5(4):180-188.
25. Gordon MA, Graham SM, Walsh AL, Wilson L, Phiri A, Molyneux E, Zijlstra EE,
Heyderman RS, Hart CA, Molyneux ME: Epidemics of invasive Salmonella
enterica serovar enteritidis and S. enterica Serovar typhimurium
infection associated with multidrug resistance among adults and
children in Malawi. Clin Infect Dis 2008, 46(7):963-969.
26. Enwere G, Biney E, Cheung YB, Zaman SM, Okoko B, Oluwalana C,
Vaughan A, Greenwood B, Adegbola R, Cutts FT: Epidemiologic and
clinical characteristics of community-acquired invasive bacterial
infections in children aged 2-29 months in The Gambia. Pediatr Infect Dis
J 2006, 25(8):700-705.
27. Ikumapayi UN, Antonio M, Sonne-Hansen J, Biney E, Enwere G, Okoko B,
Oluwalana C, Vaughan A, Zaman SM, Greenwood BM, et al: Molecular
epidemiology of community-acquired invasive non-typhoidal Salmonella
among children aged 2 29 months in rural Gambia and discovery of a
new serovar, Salmonella enterica Dingiri. J Med Microbiol 2007, 56(Pt
11):1479-1484.
28. Bejon P, Mwangi I, Ngetsa C, Mwarumba S, Berkley JA, Lowe BS, Maitland K,
Marsh K, English M, Scott JA: Invasive Gram-negative bacilli are frequently
resistant to standard antibiotics for children admitted to hospital in
Kilifi, Kenya. J Antimicrob Chemother 2005, 56(1):232-235.
29. Blomberg B, Manji KP, Urassa WK, Tamim BS, Mwakagile DS, Jureen R,
Msangi V, Tellevik MG, Holberg-Petersen M, Harthug S, et al: Antimicrobial
resistance predicts death in Tanzanian children with bloodstream
infections: a prospective cohort study. BMC Infect Dis 2007, 7:43.
30. Mills-Robertson F, Crupper SS, Addy ME, Mensah P: Antibiotic resistance
and genotyping of clinical group B Salmonella isolated in Accra, Ghana.
J Appl Microbiol 2003, 94(2):289-294.
31. Djie-Maletz A, Reither K, Danour S, Anyidoho L, Saad E, Danikuu F, Ziniel P,
Weitzel T, Wagner J, Bienzle U, et al: High rate of resistance to locally
used antibiotics among enteric bacteria from children in Northern
Ghana. J Antimicrob Chemother 2008, 61(6):1315-1318.
32. Weinberger M, Keller N: Recent trends in the epidemiology of non-
typhoid Salmonella and antimicrobial resistance: the Israeli experience
and worldwide review. Curr Opin Infect Dis 2005, 18(6):513-521.
33. Holliman RE, Liddy H, Johnson JD, Adjei O: Epidemiology of invasive
pneumococcal disease in Kumasi, Ghana. Transactions of the Royal Society
of Tropical Medicine and Hygiene 2007, 101(4):405-413.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/10/319/prepub
doi:10.1186/1471-2334-10-319
Cite this article as: Schwarz et al.: Systemic bacteraemia in children
presenting with clinical pneumonia and the impact of non-typhoid
salmonella (NTS). BMC Infectious Diseases 2010 10:319.
Schwarz et al. BMC Infectious Diseases 2010, 10:319
http://www.biomedcentral.com/1471-2334/10/319
Page 5 of 5
